JPRN-jRCT1080220856未知4 期
Post-marketing clinical study of Topina tablets in patients with partial epilepsy (incremental dose comparative study)
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 180 人开始时间: 2009年9月9日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Patients who continue the treatment of one or more antiepileptic drugs with same usage and dosage except Topina tablets
- •Patients who experience one or more partial seizures in every four weeks regardless of the treatment of antiepileptic drugs except Topina tablets
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Post-market clinical follow-up investigation of the marketed Extended Range of Vision IOL (Intraocular lens)h25H26Senile cataractOther cataractDRKS00005742Abbott Medical Optics Inc.147
未知
4 期
Post-Marketing Clinical Study of ReQuip Tablets in Patients with Parkinson's Disease -Evaluation of Long-Term Efficacy and SafetyParkinson's DiseaseJPRN-jRCT1080220387GlaxoSmithKline K.K.100
已完成
2 期
The effect of Tarooneh on paiIRCT2017063034815N1Arak University of Medical Sciences70
进行中（未招募）
不适用
Phase IIB Dose Response and Safety Study of Topical Formulationsof Methotrexate (MQX-5902, MQX-5904 and MQX-5906)in the Treatment of Fingernail Psoriasis - MQT NailPsoriasis of the fingernailEUCTR2006-004346-17-GBMediquest Therapeutics Inc83
已完成
2 期
Dose response and safety study of topical methotrexate for the treatment of fingernail psoriasisISRCTN62739763MediQuest Therapeutics, Inc. (USA)83